We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Tag: major depressive disorder
MedXY News
EnglishTag

major depressive disorder

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Navigating Conflicting Clinical Trial Evidence: The FDA’s Approval Journey of Gepirone Extended Release for Major Depression
newsclinical trial evaluationgepirone ER

Navigating Conflicting Clinical Trial Evidence: The FDA’s Approval Journey of Gepirone Extended Release for Major Depression

By MedXY|Aug 11, 2026

This article critically examines the FDA’s approval of gepirone ER for major depressive disorder despite multiple negative trials, highlighting regulatory flexibility, statistical and clinical considerations, and implications for tran

Semaglutide Reduced Effort Discounting and Improved Motivation Signals in Major Depressive Disorder
Diabetes & EndocrinologyGLP-1 receptor agonist
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
major depressive disorder

Semaglutide Reduced Effort Discounting and Improved Motivation Signals in Major Depressive Disorder

By MedXY|May 5, 2026

In a 16-week randomized trial, adjunctive oral semaglutide improved effort-based decision-making in adults with major depressive disorder and overweight or obesity, suggesting a potential role for GLP-1 receptor agonism in reward-related dy

Synergistic Neuromodulation: Combined rTMS and tDCS Outperform Monotherapy in Patients with Anxious Depression
newsmajor depressive disorderneuromodulation

Synergistic Neuromodulation: Combined rTMS and tDCS Outperform Monotherapy in Patients with Anxious Depression

By MedXY|Feb 23, 2026

A double-blind RCT involving 240 patients reveals that combining rTMS and tDCS significantly improves remission rates and symptom reduction in Major Depressive Disorder with comorbid anxiety compared to single-modality or sham treatments, p

Rest-Activity Rhythms as Digital Biomarkers: Predicting Relapse in Major Depressive Disorder via Actigraphy
newsactigraphycircadian rhythms

Rest-Activity Rhythms as Digital Biomarkers: Predicting Relapse in Major Depressive Disorder via Actigraphy

By MedXY|Feb 21, 2026

A landmark one-year actigraphy study reveals that sleep phase variability and daily activity amplitude are significant objective markers for predicting MDD relapse, offering a scalable path toward personalized, preventive psychiatric care.

Decoding Antidepressant Response: Genetic and Phenotypic Markers of Treatment Complexity and Sustained Use
newsantidepressantsmajor depressive disorder

Decoding Antidepressant Response: Genetic and Phenotypic Markers of Treatment Complexity and Sustained Use

By MedXY|Jan 31, 2026

A large-scale retrospective cohort study identifies specific phenotypic traits and genetic markers, including the SLAMF3/LY9 locus, that predict antidepressant treatment complexity and sustained use, offering a roadmap for precision psychia

Adjunctive Omega-3 Supplementation Does Not Improve Pediatric Major Depressive Disorder: Insights from a Multi-Center Randomized Trial
newsclinical trialmajor depressive disorder

Adjunctive Omega-3 Supplementation Does Not Improve Pediatric Major Depressive Disorder: Insights from a Multi-Center Randomized Trial

By MedXY|Jan 6, 2026

A multi-center randomized clinical trial involving 257 youths found that adjunctive omega-3 fatty acids (1.5 g/d) did not outperform placebo in treating moderate-to-severe pediatric major depressive disorder, despite high adherence and conc

Systemic Inflammation as a Modulator of Anhedonia in Major Depressive Disorder: Insights from an LPS Challenge Trial
newsAnhedoniamajor depressive disorder

Systemic Inflammation as a Modulator of Anhedonia in Major Depressive Disorder: Insights from an LPS Challenge Trial

By MedXY|Oct 31, 2025

This RCT reveals that adults with major depressive disorder and elevated systemic inflammation exhibit heightened anhedonic responses to an inflammatory challenge, highlighting inflammation’s role in depression symptomatology.

Harnessing Effective Connectivity Between Cerebellum and Fronto-Temporal Regions for Objective Major Depressive Disorder Diagnosis: Insights From a Multi-Site fMRI Study
NeurologyfMRImajor depressive disorder

Harnessing Effective Connectivity Between Cerebellum and Fronto-Temporal Regions for Objective Major Depressive Disorder Diagnosis: Insights From a Multi-Site fMRI Study

By MedXY|Oct 30, 2025

A multi-site fMRI study demonstrates that effective connectivity patterns between the cerebellum and fronto-temporal areas accurately classify major depressive disorder with over 94% accuracy, offering a promising neuroimaging biomarker to

Azetukalner: A Novel KV7 Potassium Channel Opener Shows Promise in Treating Major Depressive Disorder
newsAnhedoniamajor depressive disorder

Azetukalner: A Novel KV7 Potassium Channel Opener Shows Promise in Treating Major Depressive Disorder

By MedXY|Oct 21, 2025

Azetukalner, a KV7 potassium channel opener, demonstrated clinically meaningful antidepressant effects and significant improvement in anhedonia in adults with major depressive disorder in a 6-week randomized trial, supporting further develo

Soft Drink Consumption and Depression: The Gut Microbiome Connection, Especially Eggerthella
Family Medicine & Nutritiongut microbiomemajor depressive disorder

Soft Drink Consumption and Depression: The Gut Microbiome Connection, Especially Eggerthella

By MedXY|Oct 9, 2025

This analysis explores how soft drink consumption correlates with major depressive disorder (MDD), revealing gut microbiome alterations—particularly in Eggerthella abundance—that may mediate this association, highlighting potential interven

Ammoxetine Shows Promise as Effective and Well-Tolerated Treatment for Major Depressive Disorder: Insights from a Phase 2 Randomized Trial
Clinical Updatesmajor depressive disorderrandomized clinical trial

Ammoxetine Shows Promise as Effective and Well-Tolerated Treatment for Major Depressive Disorder: Insights from a Phase 2 Randomized Trial

By MedXY|Oct 9, 2025

A phase 2 trial in adults with major depressive disorder demonstrated that ammoxetine at 40 mg/d and 60 mg/d significantly improved depressive symptoms compared to placebo and was generally well tolerated, offering a novel treatment option

Harnessing AI for Personalized Depression Treatment: Insights from the AID-ME Cluster Randomized Trial
AIartificial intelligenceclinical decision support system

Harnessing AI for Personalized Depression Treatment: Insights from the AID-ME Cluster Randomized Trial

By MedXY|Oct 7, 2025

The AID-ME trial demonstrates that an AI-powered clinical decision support system significantly improves remission rates and accelerates symptom improvement in moderate to severe major depressive disorder.

Accelerating Depression Recovery: The Impact of Measurement-Based Care in Pakistan’s Low-Resource Settings
Clinical UpdatesLow- and Middle-Income Countriesmajor depressive disorder

Accelerating Depression Recovery: The Impact of Measurement-Based Care in Pakistan’s Low-Resource Settings

By MedXY|Oct 7, 2025

A randomized clinical trial in Pakistan demonstrates that measurement-based care accelerates antidepressant treatment response and remission in major depressive disorder compared to standard care, underscoring its potential in low-resource

Optimizing Smoking Cessation in Major Depressive Disorder: Varenicline Outperforms Bupropion and Nicotine Patch with Comparable Safety
Clinical Updatesmajor depressive disordernicotine replacement therapy

Optimizing Smoking Cessation in Major Depressive Disorder: Varenicline Outperforms Bupropion and Nicotine Patch with Comparable Safety

By MedXY|Oct 5, 2025

This analysis reveals that varenicline is the most effective and safe pharmacotherapy for smoking cessation in individuals with current or past major depressive disorder, outperforming bupropion and nicotine patches with no increased neurop

Exploring Over-the-Counter Herbal and Nutritional Products for Adult Depression: A Comprehensive Evidence Landscape
Clinical Updatesdepressiondietary supplements

Exploring Over-the-Counter Herbal and Nutritional Products for Adult Depression: A Comprehensive Evidence Landscape

By MedXY|Aug 18, 2025

A scoping review of 209 trials reveals a concentrated evidence base for omega-3s, St John’s Wort, saffron, probiotics, and vitamin D in treating adult depression, highlights promising but under-researched herbal and supplement candidates, a

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities